Alnylam Gets VIP Status as the FDA Slaps Breakthrough Tag on Patisiran Post author:Sam Post published:November 19, 2017 Post category:BioPharma The company is weeks away from completing its rolling NDA for Patisiran. Source: BioSpace You Might Also Like Bristol-Myers Squibb's Opdivo Prevails in Phase III Melanoma Trial July 4, 2017 How Immigration Ban is Already Hurting Science January 29, 2017 OPKO Health’s Annual Report a Mixed Bag March 1, 2018
